Matching articles for "Fentanyl"
Issue 1665 · December 12, 2022
Opioids for Pain

A new CDC guideline for prescribing opioids for pain recently became available. Nonopioid drugs for pain were reviewed in a previous issue.

Med Lett Drugs Ther. 2022 Dec 12; 64(1665):193-200
A new CDC guideline for prescribing opioids for pain recently became available. Nonopioid drugs for pain were reviewed in a previous issue.
Issue 1665 · December 12, 2022
Comparison Table: Some Oral/Transdermal Opioid Analgesics (online only)

View the Comparison Table: Some Oral/Transdermal Opioid Analgesics

Med Lett Drugs Ther. 2022 Dec 12; 64(1665):e199-202
View the Comparison Table: Some Oral/Transdermal Opioid Analgesics
Issue 1544 · April 9, 2018
Opioids for Pain

Use of nonopioid drugs for pain was reviewed in a previous issue. For many types of moderate to severe acute pain, acetaminophen and/or an NSAID may be as effective as an opioid. Immediate-release formulations…

Med Lett Drugs Ther. 2018 Apr 9; 60(1544):57-64
Use of nonopioid drugs for pain was reviewed in a previous issue. For many types of moderate to severe acute pain, acetaminophen and/or an NSAID may be as effective as an opioid. Immediate-release formulations of full opioid agonists should generally be used for acute pain that is severe enough to require treatment with an opioid. Use of extended-release or long-acting opioid formulations initially and treatment durations >1 week have been associated with an increased risk of unintended long-term use.
Issue 1544 · April 9, 2018
Comparison Table: Some Oral/Topical Opioid Analgesics (online only)

View the Comparison Table: Some Oral/Topical Opioid Analgesics

Med Lett Drugs Ther. 2018 Apr 9; 60(1544):e64-7
View the Comparison Table: Some Oral/Topical Opioid Analgesics
Issue 1481 · November 9, 2015
Transdermal Fentanyl (Ionsys) for Postoperative Pain

A patient-controlled fentanyl iontophoretic transdermal system ( Ionsys – The Medicines Company) is now available for short-term management of acute postoperative pain in adults requiring opioid analgesia in…

Med Lett Drugs Ther. 2015 Nov 9; 57(1481):155-6
A patient-controlled fentanyl iontophoretic transdermal system ( Ionsys – The Medicines Company) is now available for short-term management of acute postoperative pain in adults requiring opioid analgesia in the hospital. Before using Ionsys , patients must be titrated to a comfortable level of analgesia with another opioid formulation.
Issue 128 · April 1, 2013
Drugs for Pain

Pain can be acute or chronic. The two major types of chronic pain are nociceptive pain and neuropathic pain. Nociceptive pain can be treated with nonopioid analgesics or opioids. Neuropathic pain is less…

Treat Guidel Med Lett. 2013 Apr; 11(128):31-42
Pain can be acute or chronic. The two major types of chronic pain are nociceptive pain and neuropathic pain. Nociceptive pain can be treated with nonopioid analgesics or opioids. Neuropathic pain is less responsive to opioids and is often treated with adjuvant drugs such as antidepressants and antiepileptics. Combining different types of analgesics may provide an additive analgesic effect without increasing adverse effects.
Issue 1379 · December 12, 2011
Fentanyl Nasal Spray (Lazanda) for Pain

The FDA has approved a nasal spray formulation of fentanyl ( Lazanda – Archimedes) for management of breakthrough pain in adult cancer patients who are already receiving and are tolerant to opioid therapy.…

Med Lett Drugs Ther. 2011 Dec 12; 53(1379):99-100
The FDA has approved a nasal spray formulation of fentanyl ( Lazanda – Archimedes) for management of breakthrough pain in adult cancer patients who are already receiving and are tolerant to opioid therapy. Fentanyl is already available in the US for intravenous, intrathecal, epidural, transdermal and oral transmucosal use.
Issue 1364 · May 16, 2011 Free
In Brief: Fentanyl Sublingual Tablets (Abstral) for Breakthrough Cancer Pain

The FDA has approved the marketing of fentanyl sublingual tablets ( Abstral – ProStrakan) for treatment of breakthrough pain in adult cancer patients who are already receiving and are tolerant to opioid…

Med Lett Drugs Ther. 2011 May 16; 53(1364):40
The FDA has approved the marketing of fentanyl sublingual tablets ( Abstral – ProStrakan) for treatment of breakthrough pain in adult cancer patients who are already receiving and are tolerant to opioid therapy. It is the fourth transmucosal formulation of fentanyl to become available in the US for this indication. 1-3 The manufacturer recommends an initial dose of 100 mcg, a maximum of 2 doses per breakthrough pain episode, and use for no more than 4 breakthrough pain episodes per day. As with all formulations of fentanyl, strong inhibitors of CYP3A4 such as clarithromycin ( Biaxin , and others) or itraconazole ( Sporanox , and others) can increase serum concentrations of the drug to levels that can cause respiratory depression even in opioid- tolerant patients. A single dose of any formulation of transmucosal fentanyl could be fatal for a child. 1. Fentanyl buccal tablet (Fentora) for breakthrough pain. Med Lett Drugs Ther 2007; 49:78. 2. Drugs for pain. Treat Guidel Med Lett 2010; 8:25. 3. Fentanyl buccal soluble film (Onsolis) for breakthrough cancer pain. Med Lett Drugs Ther 2010; 52:30. Download U.S. English
Issue 1362 · April 18, 2011
Transdermal Buprenorphine (Butrans) for Chronic Pain

The FDA has approved the partial opioid agonist buprenorphine in a transdermal formulation ( Butrans – Purdue) for treatment of moderate to severe chronic pain. Buprenorphine has been available in the US for…

Med Lett Drugs Ther. 2011 Apr 18; 53(1362):31-2
The FDA has approved the partial opioid agonist buprenorphine in a transdermal formulation ( Butrans – Purdue) for treatment of moderate to severe chronic pain. Buprenorphine has been available in the US for years in parenteral formulations for pain and in sublingual tablets for opioid dependence.1 Transdermal buprenorphine has been available in Europe for several years.2
Issue 1336 · April 19, 2010
Fentanyl Buccal Soluble Film (Onsolis) for Breakthrough Cancer Pain

Fentanyl buccal soluble film ( Onsolis – Meda) has been approved by the FDA for treatment of breakthrough pain in adult cancer patients who are already taking and are tolerant to around-the-clock opioid…

Med Lett Drugs Ther. 2010 Apr 19; 52(1336):30-1
Fentanyl buccal soluble film ( Onsolis – Meda) has been approved by the FDA for treatment of breakthrough pain in adult cancer patients who are already taking and are tolerant to around-the-clock opioid therapy. It is designated as a Schedule II controlled substance Two other oral transmucosal formulations of fentanyl are already available for this indication.
Issue 92 · April 1, 2010
Drugs for Pain

Pain can be acute or chronic. Chronic pain has been broadly classified into two types: nociceptive and neuropathic. Nociceptive pain can be treated with nonopioid analgesics or opioids. Neuropathic pain is…

Treat Guidel Med Lett. 2010 Apr; 8(92):25-34
Pain can be acute or chronic. Chronic pain has been broadly classified into two types: nociceptive and neuropathic. Nociceptive pain can be treated with nonopioid analgesics or opioids. Neuropathic pain is less responsive to opioids; adjuvant medicines such as antidepressants and anticonvulsants are often used to treat neuropathic pain. Combining different types of analgesics may provide an additive analgesic effect without increasing adverse effects.
Issue 1318 · August 10, 2009 Free
In Brief: Heat and Transdermal Fentanyl

Transdermal fentanyl ( Duragesic , and others) offers a convenient delivery system for patients with chronic pain 1 but it has some drawbacks. One is that exposing the patch to heat, either from an external…

Med Lett Drugs Ther. 2009 Aug 10; 51(1318):64
Transdermal fentanyl ( Duragesic , and others) offers a convenient delivery system for patients with chronic pain 1 but it has some drawbacks. One is that exposing the patch to heat, either from an external source, increased exertion or possibly high fever, could increase release of the drug, which might lead to an overdose and fatal respiratory depression. 2 A recent article in the NY Times about this problem may have aroused the concerns of some patients using the patches. 3 First approved for marketing by the FDA in 1991 4 , transdermal fentanyl provides continuous delivery of the drug for about 3 days. After application of the patch, a depot of fentanyl forms in the upper layers of the skin. Serum concentrations of the drug increase gradually, reaching a peak (Cmax) in 24-72 hours. According to a pharmacokinetic model mentioned in the labeling, an increase in body temperature to 40°C (104°F) could increase fentanyl serum concentrations by 33%. Local application of heat near or on a fentanyl transdermal patch also increases systemic absorption; in one study, heating the patch during the first 4 hours after application increased maximum serum concentrations nearly three-fold. 5 Unintentional increases in systemic fentanyl absorption caused by a heating pad, a warming blanket used during surgery and strenuous exertion have led to respiratory depression in 3 patients. 6 No reports of clinical overdosage caused by fever have been published. Serious adverse events may require removal of the patch and administration of an opioid antagonist such as naloxone ( Narcan , and others). Monitoring for hypoventilation or cognitive impairment for at least 24 hours is recommended after removing the patch because fentanyl concentrations decrease slowly (50% decrease in about 17 hours) due to continued systemic absorption from the intracutaneous reservoir. 1. Drugs for pain. Treat Guidel Med Lett 2007; 5:23. 2. FDA Alert 7/15/2005; Update 12/21/2007. Information for healthcare professionals: Fentanyl transdermal system (marketed as Duragesic and generics). Available at www.fda.gov/cder/drug/InfoSheets/HCP/fentanyl_2007HCP.htm. Accessed July 27, 2009. 3. T Brown. Doctors and nurses, still learning. New York Times, April 29, 2009. Available at NYTimes.com. Accessed July 29, 2009. 4. Transdermal fentanyl. Med Lett Drugs Ther 1992; 34:97. 5. MA Ashburn et al. The pharmacokinetics of transdermal fentanyl delivered with and without controlled heat. J Pain 2003; 4:291. 6. KA Carter. Heat-associated increase in transdermal fentanyl absorption. Am J Health Syst Pharm 2003; 60:191. Download: U.S. English
Issue 1270 · September 24, 2007
Fentanyl Buccal Tablet (Fentora) for Breakthrough Pain

The FDA has approved a transmucosal tablet formulation of fentanyl citrate ( Fentora - Cephalon) for management of breakthrough pain in opioid-tolerant patients with cancer. An oral transmucosal fentanyl…

Med Lett Drugs Ther. 2007 Sep 24; 49(1270):79-6
The FDA has approved a transmucosal tablet formulation of fentanyl citrate ( Fentora - Cephalon) for management of breakthrough pain in opioid-tolerant patients with cancer. An oral transmucosal fentanyl lozenge on a stick ( Actiq , and others) is also available for this indication, and is widely used off-label for chronic, non-cancer pain as well.
Issue 56 · April 1, 2007
Drugs for Pain

Pain can be acute or chronic. Chronic pain has been broadly classified into two types: nociceptive and neuropathic. Nociceptive pain is generally treated with nonopioid analgesics and opioids. Antidepressants…

Treat Guidel Med Lett. 2007 Apr; 5(56):23-32
Pain can be acute or chronic. Chronic pain has been broadly classified into two types: nociceptive and neuropathic. Nociceptive pain is generally treated with nonopioid analgesics and opioids. Antidepressants and anticonvulsants have been used to treat neuropathic pain. Combining two different types of analgesics may nprovide an additive analgesic effect without increasing adverse effects.
Issue 1214 · August 1, 2005 Free
In Brief: Palladone Withdrawn

The Medical Letter review of Palladone (hydromorphone HCl) extended-release capsules (March 14, 2005) warned that a lethal dose could be released if the new formulation was taken with alcohol. Because of that…

Med Lett Drugs Ther. 2005 Aug 1; 47(1214):61
The Medical Letter review of Palladone (hydromorphone HCl) extended-release capsules (March 14, 2005) warned that a lethal dose could be released if the new formulation was taken with alcohol. Because of that risk, the FDA asked the manufacturer (Purdue) to withdraw the drug from the market (FDA News. July 13, 2005; FDC Reports – “The Pink Sheet” July 18, 2005; 67:3) .
Issue 1212 · July 4, 2005
CYP3A and Drug Interactions

Serious adverse interactions between drugs continue to be reported. Many of these are due to inhibition or induction of cytochrome P450 (CYP) enzymes, particularly CYP3A4. CYP3A is thought to be involved in…

Med Lett Drugs Ther. 2005 Jul 4; 47(1212):54-5
Serious adverse interactions between drugs continue to be reported. Many of these are due to inhibition or induction of cytochrome P450 (CYP) enzymes, particularly CYP3A4. CYP3A is thought to be involved in the metabolism of more than 50 percent of currently prescribed drugs.2 CYP3A4, which is more abundantly expressed than CYP3A5, accounts for most CYP3A activity in vivo .
Issue 1204 · March 14, 2005
Palladone for Chronic Pain

A once-daily extended-release (ER) oral formulation of the opioid analgesic hydromorphone hydrochloride ( Palladone - Purdue Pharma) has been approved by the FDA for treatment of opioid-tolerant patients with…

Med Lett Drugs Ther. 2005 Mar 14; 47(1204):21-3
A once-daily extended-release (ER) oral formulation of the opioid analgesic hydromorphone hydrochloride ( Palladone - Purdue Pharma) has been approved by the FDA for treatment of opioid-tolerant patients with persistent moderate to severe pain. Hydromorphone HCl, a semisynthetic congener of morphine and active metabolite of hydrocodone that has been used since the 1920s, is also available in immediate-release oral, injectable and suppository forms ( Dilaudid , and others).
Issue 23 · July 1, 2004
Drugs for Pain

Three types of analgesic drugs are available: non-opioids, including aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; opioids; and adjuvant drugs that are not usually thought of…

Treat Guidel Med Lett. 2004 Jul; 2(23):47-54
Three types of analgesic drugs are available: non-opioids, including aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; opioids; and adjuvant drugs that are not usually thought of as analgesics, such as antidepressants, which can act as adjuvants when given with NSAIDs or opioids, or have analgesic activity of their own in some types of pain. Combining two different types of analgesics may provide an additive analgesic effect without necessarily increasing adverse effects.
Issue 1158 · June 8, 2003
Drug Interactions

Changes caused by one drug in the absorption, distribution, metabolism or excretion of another may lead to a pharmacokinetic adverse drug interaction (DN Juurlink et al, JAMA 2003; 289:1652). Additive drug…

Med Lett Drugs Ther. 2003 Jun 8; 45(1158):46-8
Changes caused by one drug in the absorption, distribution, metabolism or excretion of another may lead to a pharmacokinetic adverse drug interaction (DN Juurlink et al, JAMA 2003; 289:1652). Additive drug interactions, such as vasodilation caused by both sildenafil (Viagra) and nitrates, can also have adverse effects.
Issue 1125 · March 4, 2002
Acute Reactions to Drugs of Abuse

Acute toxic reactions to drugs of abuse continue to be important problems. Some patients may have mixed intoxications with complex combinations of signs and symptoms.

Med Lett Drugs Ther. 2002 Mar 4; 44(1125):21-4
Acute toxic reactions to drugs of abuse continue to be important problems. Some patients may have mixed intoxications with complex combinations of signs and symptoms.
Issue 1085 · August 21, 2000
Drugs for Pain

Three types of analgesic drugs are available: first, non-opioids, including aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; second, opioids; and third, drugs not usually thought…

Med Lett Drugs Ther. 2000 Aug 21; 42(1085):73-8
Three types of analgesic drugs are available: first, non-opioids, including aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; second, opioids; and third, drugs not usually thought of as analgesics, which act as adjuvants when given with NSAIDs or opioids, or have analgesic activity of their own in some types of pain. Non-opioids can be given concurrently with opioids for an additive analgesic effect.
Issue 1056 · July 2, 1999
Drug Interactions

Reports of adverse interactions between drugs continue to accumulate. Recently, the FDA has expanded the recommendations on drug interactions found in the package inserts of new drugs.

Med Lett Drugs Ther. 1999 Jul 2; 41(1056):59-62
Reports of adverse interactions between drugs continue to accumulate. Recently, the FDA has expanded the recommendations on drug interactions found in the package inserts of new drugs.
Issue 1033 · August 14, 1998
Drugs for Pain

Three types of analgesic drugs are available: first, non-opioids, including aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; second, opioids; and third, some drugs not usually…

Med Lett Drugs Ther. 1998 Aug 14; 40(1033):79-84
Three types of analgesic drugs are available: first, non-opioids, including aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; second, opioids; and third, some drugs not usually thought of as analgesics, which act as adjuvants when given with NSAIDs or opioids, or have analgesic activity of their own in some types of pain.
Issue 1022 · March 13, 1998
Sibutramine for Obesity

Sibutramine hydrochlorid monohydreate ( Meridia - Knoll), which is structurally related to amphetamine, has been approved by the FDA for treatment of obesity. It is classified by the Drug Enforcement Agency…

Med Lett Drugs Ther. 1998 Mar 13; 40(1022):32
Sibutramine hydrochlorid monohydreate ( Meridia - Knoll), which is structurally related to amphetamine, has been approved by the FDA for treatment of obesity. It is classified by the Drug Enforcement Agency (DEA) as a schedule IV controlled substance.
Issue 974 · May 10, 1996
Acute Reactions to Drugs of Abuse

Acute toxic reactions to drugs of abuse continue to be important problems. Since the last Medical Letter article on this subject (volume 32, page 92, 1990), new reactions and new approaches to treating them…

Med Lett Drugs Ther. 1996 May 10; 38(974):43-6
Acute toxic reactions to drugs of abuse continue to be important problems. Since the last Medical Letter article on this subject (volume 32, page 92, 1990), new reactions and new approaches to treating them have been reported.
Issue 960 · October 27, 1995
Nalmefene - Long-Acting Injectable Opioid Antagonist

Nalmefene ( Revex - Ohmeda), an i methylene analog of naltrexone ( Trexan ), is a long-acting opioid antagonist that has been approved by the US Food and Drug Administration for reversal of postoperative…

Med Lett Drugs Ther. 1995 Oct 27; 37(960):97-8
Nalmefene ( Revex - Ohmeda), an i methylene analog of naltrexone ( Trexan ), is a long-acting opioid antagonist that has been approved by the US Food and Drug Administration for reversal of postoperative opioid drug effects, including respiratory depression, sedation and hypotension and for management of known or suspected opioid overdose in the emergency department. The only other opioid antagonists available in the USA are naloxone ( Narcan ), which is also injectable but has a short duration of action, and naltrexone, which has a long duration of action but is marketed only for oral use.
Issue 887 · January 8, 1993
Drugs for Pain

Three types of analgesic drugs are available in the USA: first, aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; second, opioids; and third, drugs not usually thought of as…

Med Lett Drugs Ther. 1993 Jan 8; 35(887):1-6
Three types of analgesic drugs are available in the USA: first, aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; second, opioids; and third, drugs not usually thought of as analgesics, which act as adjuvants when given with NSAIDs or opioids, or have analgesic activity of their own in some types of pain. (American Pain Society, Principles of analgesic Use , 3rd ed, Skokie, illinois: American pain society, 1992).
Issue 881 · October 16, 1992
Transdermal Fentanyl

Fentanyl, a synthetic opioid previously available for parenteral use in anesthesia ( Sublimaze ), has now been marketed in a controlled-release transdermal formulation ( Duragesic - Janssen) for use in…

Med Lett Drugs Ther. 1992 Oct 16; 34(881):97-8
Fentanyl, a synthetic opioid previously available for parenteral use in anesthesia ( Sublimaze ), has now been marketed in a controlled-release transdermal formulation ( Duragesic - Janssen) for use in patients with chronic pain severe enough to require opioid analgesia. It is not recommended for treatment of postoperative pain because of the drug's slow onset and prolonged duration of action.
Issue 836 · January 25, 1991
Laser Coronary Angioplasty

Percutaneous transluminal coronary angioplasty (PTCA), in which a balloon catheter distends the vessel at the site of obstruction (Medical Letter, 25:97, 1983), is now an established therapeutic option for…

Med Lett Drugs Ther. 1991 Jan 25; 33(836):7-8
Percutaneous transluminal coronary angioplasty (PTCA), in which a balloon catheter distends the vessel at the site of obstruction (Medical Letter, 25:97, 1983), is now an established therapeutic option for treatment of patients with coronary artery disease, especially those with single-vessel disease. Major problems related to PTCA include acute occlusion during the procedure (usually caused by dissection), restenosis at the site of angioplasty, and inability to treat complete occlusions and long or ostial lesions. Some cardiologists have tried using lasers during PTCA to deal with these problems.
Issue 828 · October 5, 1990
Acute Reactions to Drugs of Abuse
Med Lett Drugs Ther. 1990 Oct 5; 32(828):92-4